Global Oncology Drugs Market 2025 by Company, Regions, Type and Application, Forecast to 2031
According to our (Global Info Research) latest study, the global Oncology Drugs market size was valued at US$ 246800 million in 2024 and is forecast to a readjusted size of USD 454310 million by 2031 with a CAGR of 9.1% during review period.
Oncology drugs are pharmaceutical agents used to prevent, treat, or manage various types of cancer. This category includes chemotherapy, targeted therapies, immunotherapies, hormone therapies, and emerging treatments such as cell-based therapies like CAR-T. These drugs function through different mechanisms, such as inhibiting cancer cell growth, inducing apoptosis, blocking angiogenesis, or enhancing the immune system’s ability to recognize and destroy malignant cells. Oncology drugs play a critical role in modern medicine and represent one of the most dynamic and innovative sectors in the pharmaceutical industry.
The oncology drugs market is experiencing robust growth driven by the increasing global burden of cancer and rising awareness of early diagnosis and treatment. Aging populations, lifestyle-related risk factors such as smoking, poor diet, and lack of physical activity, along with environmental exposures, have all contributed to higher cancer incidence rates. Technological advancements in molecular biology and genomics have accelerated the development of targeted therapies, immunotherapies, and personalized medicine, which offer improved efficacy with fewer side effects. Governments and health organizations worldwide are increasing investments in cancer research, diagnostics, and treatment infrastructure, further supporting market expansion. Additionally, the growing adoption of biosimilars and the introduction of new drug classes like CAR-T cell therapies and checkpoint inhibitors are enhancing treatment options and accessibility for patients across various cancer types.
Despite significant progress, the oncology drugs market faces notable challenges. One of the key issues is the high cost of cancer drugs, particularly biologics and targeted therapies, which poses a financial burden on healthcare systems and patients, especially in low- and middle-income countries. Drug development in oncology is highly complex, expensive, and time-consuming, with a high failure rate during clinical trials. Regulatory hurdles, including long approval timelines and stringent safety requirements, can delay the introduction of innovative therapies. Moreover, the emergence of drug resistance in certain cancers, such as melanoma or non-small cell lung cancer, limits the long-term effectiveness of current treatments. Inequitable access to oncology care, due to disparities in healthcare infrastructure, insurance coverage, and geographical availability, further restricts market reach and poses a major public health concern globally.
This report is a detailed and comprehensive analysis for global Oncology Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Oncology Drugs market size and forecasts, in consumption value ($ Million), 2020-2031
Global Oncology Drugs market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Oncology Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Oncology Drugs market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Oncology Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Oncology Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Oncology Drugs market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Oncology Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Oncology Drugs, with revenue, gross margin, and global market share of Oncology Drugs from 2020 to 2025.
Chapter 3, the Oncology Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Oncology Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Oncology Drugs.
Chapter 13, to describe Oncology Drugs research findings and conclusion.
Oncology drugs are pharmaceutical agents used to prevent, treat, or manage various types of cancer. This category includes chemotherapy, targeted therapies, immunotherapies, hormone therapies, and emerging treatments such as cell-based therapies like CAR-T. These drugs function through different mechanisms, such as inhibiting cancer cell growth, inducing apoptosis, blocking angiogenesis, or enhancing the immune system’s ability to recognize and destroy malignant cells. Oncology drugs play a critical role in modern medicine and represent one of the most dynamic and innovative sectors in the pharmaceutical industry.
The oncology drugs market is experiencing robust growth driven by the increasing global burden of cancer and rising awareness of early diagnosis and treatment. Aging populations, lifestyle-related risk factors such as smoking, poor diet, and lack of physical activity, along with environmental exposures, have all contributed to higher cancer incidence rates. Technological advancements in molecular biology and genomics have accelerated the development of targeted therapies, immunotherapies, and personalized medicine, which offer improved efficacy with fewer side effects. Governments and health organizations worldwide are increasing investments in cancer research, diagnostics, and treatment infrastructure, further supporting market expansion. Additionally, the growing adoption of biosimilars and the introduction of new drug classes like CAR-T cell therapies and checkpoint inhibitors are enhancing treatment options and accessibility for patients across various cancer types.
Despite significant progress, the oncology drugs market faces notable challenges. One of the key issues is the high cost of cancer drugs, particularly biologics and targeted therapies, which poses a financial burden on healthcare systems and patients, especially in low- and middle-income countries. Drug development in oncology is highly complex, expensive, and time-consuming, with a high failure rate during clinical trials. Regulatory hurdles, including long approval timelines and stringent safety requirements, can delay the introduction of innovative therapies. Moreover, the emergence of drug resistance in certain cancers, such as melanoma or non-small cell lung cancer, limits the long-term effectiveness of current treatments. Inequitable access to oncology care, due to disparities in healthcare infrastructure, insurance coverage, and geographical availability, further restricts market reach and poses a major public health concern globally.
This report is a detailed and comprehensive analysis for global Oncology Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Oncology Drugs market size and forecasts, in consumption value ($ Million), 2020-2031
Global Oncology Drugs market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Oncology Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Oncology Drugs market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Oncology Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Oncology Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Oncology Drugs market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Chemotherapy
- Targeted Therapy
- Immunotherapy (Biologic Therapy)
- Hormonal Therapy
- Others
- Blood Cancer
- Breast Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Respiratory or Lung Cancer
- Others
- Roche
- Celgene
- Novartis
- Bristol-Myers Squibb
- Johnson & Johnson
- Merck & Co.
- AstraZeneca
- Pfizer
- Amgen
- Eli Lilly
- AbbVie
- Takeda
- Astellas
- Ipsen
- Sanofi
- Bayer
- Biogen Idec
- Teva
- Otsuka
- Eisai
- Merck KGaA
- Gilead Sciences
- Hengrui Medicine
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Oncology Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Oncology Drugs, with revenue, gross margin, and global market share of Oncology Drugs from 2020 to 2025.
Chapter 3, the Oncology Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Oncology Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Oncology Drugs.
Chapter 13, to describe Oncology Drugs research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Oncology Drugs by Type
1.3.1 Overview: Global Oncology Drugs Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Oncology Drugs Consumption Value Market Share by Type in 2024
1.3.3 Chemotherapy
1.3.4 Targeted Therapy
1.3.5 Immunotherapy (Biologic Therapy)
1.3.6 Hormonal Therapy
1.3.7 Others
1.4 Global Oncology Drugs Market by Application
1.4.1 Overview: Global Oncology Drugs Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Blood Cancer
1.4.3 Breast Cancer
1.4.4 Gastrointestinal Cancer
1.4.5 Prostate Cancer
1.4.6 Respiratory or Lung Cancer
1.4.7 Others
1.5 Global Oncology Drugs Market Size & Forecast
1.6 Global Oncology Drugs Market Size and Forecast by Region
1.6.1 Global Oncology Drugs Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Oncology Drugs Market Size by Region, (2020-2031)
1.6.3 North America Oncology Drugs Market Size and Prospect (2020-2031)
1.6.4 Europe Oncology Drugs Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Oncology Drugs Market Size and Prospect (2020-2031)
1.6.6 South America Oncology Drugs Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Oncology Drugs Market Size and Prospect (2020-2031)
2 COMPANY PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Oncology Drugs Product and Solutions
2.1.4 Roche Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Roche Recent Developments and Future Plans
2.2 Celgene
2.2.1 Celgene Details
2.2.2 Celgene Major Business
2.2.3 Celgene Oncology Drugs Product and Solutions
2.2.4 Celgene Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Celgene Recent Developments and Future Plans
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis Oncology Drugs Product and Solutions
2.3.4 Novartis Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Novartis Recent Developments and Future Plans
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb Details
2.4.2 Bristol-Myers Squibb Major Business
2.4.3 Bristol-Myers Squibb Oncology Drugs Product and Solutions
2.4.4 Bristol-Myers Squibb Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business
2.5.3 Johnson & Johnson Oncology Drugs Product and Solutions
2.5.4 Johnson & Johnson Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Johnson & Johnson Recent Developments and Future Plans
2.6 Merck & Co.
2.6.1 Merck & Co. Details
2.6.2 Merck & Co. Major Business
2.6.3 Merck & Co. Oncology Drugs Product and Solutions
2.6.4 Merck & Co. Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Merck & Co. Recent Developments and Future Plans
2.7 AstraZeneca
2.7.1 AstraZeneca Details
2.7.2 AstraZeneca Major Business
2.7.3 AstraZeneca Oncology Drugs Product and Solutions
2.7.4 AstraZeneca Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 AstraZeneca Recent Developments and Future Plans
2.8 Pfizer
2.8.1 Pfizer Details
2.8.2 Pfizer Major Business
2.8.3 Pfizer Oncology Drugs Product and Solutions
2.8.4 Pfizer Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Pfizer Recent Developments and Future Plans
2.9 Amgen
2.9.1 Amgen Details
2.9.2 Amgen Major Business
2.9.3 Amgen Oncology Drugs Product and Solutions
2.9.4 Amgen Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Amgen Recent Developments and Future Plans
2.10 Eli Lilly
2.10.1 Eli Lilly Details
2.10.2 Eli Lilly Major Business
2.10.3 Eli Lilly Oncology Drugs Product and Solutions
2.10.4 Eli Lilly Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Eli Lilly Recent Developments and Future Plans
2.11 AbbVie
2.11.1 AbbVie Details
2.11.2 AbbVie Major Business
2.11.3 AbbVie Oncology Drugs Product and Solutions
2.11.4 AbbVie Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 AbbVie Recent Developments and Future Plans
2.12 Takeda
2.12.1 Takeda Details
2.12.2 Takeda Major Business
2.12.3 Takeda Oncology Drugs Product and Solutions
2.12.4 Takeda Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Takeda Recent Developments and Future Plans
2.13 Astellas
2.13.1 Astellas Details
2.13.2 Astellas Major Business
2.13.3 Astellas Oncology Drugs Product and Solutions
2.13.4 Astellas Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.13.5 Astellas Recent Developments and Future Plans
2.14 Ipsen
2.14.1 Ipsen Details
2.14.2 Ipsen Major Business
2.14.3 Ipsen Oncology Drugs Product and Solutions
2.14.4 Ipsen Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.14.5 Ipsen Recent Developments and Future Plans
2.15 Sanofi
2.15.1 Sanofi Details
2.15.2 Sanofi Major Business
2.15.3 Sanofi Oncology Drugs Product and Solutions
2.15.4 Sanofi Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.15.5 Sanofi Recent Developments and Future Plans
2.16 Bayer
2.16.1 Bayer Details
2.16.2 Bayer Major Business
2.16.3 Bayer Oncology Drugs Product and Solutions
2.16.4 Bayer Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.16.5 Bayer Recent Developments and Future Plans
2.17 Biogen Idec
2.17.1 Biogen Idec Details
2.17.2 Biogen Idec Major Business
2.17.3 Biogen Idec Oncology Drugs Product and Solutions
2.17.4 Biogen Idec Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.17.5 Biogen Idec Recent Developments and Future Plans
2.18 Teva
2.18.1 Teva Details
2.18.2 Teva Major Business
2.18.3 Teva Oncology Drugs Product and Solutions
2.18.4 Teva Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.18.5 Teva Recent Developments and Future Plans
2.19 Otsuka
2.19.1 Otsuka Details
2.19.2 Otsuka Major Business
2.19.3 Otsuka Oncology Drugs Product and Solutions
2.19.4 Otsuka Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.19.5 Otsuka Recent Developments and Future Plans
2.20 Eisai
2.20.1 Eisai Details
2.20.2 Eisai Major Business
2.20.3 Eisai Oncology Drugs Product and Solutions
2.20.4 Eisai Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.20.5 Eisai Recent Developments and Future Plans
2.21 Merck KGaA
2.21.1 Merck KGaA Details
2.21.2 Merck KGaA Major Business
2.21.3 Merck KGaA Oncology Drugs Product and Solutions
2.21.4 Merck KGaA Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.21.5 Merck KGaA Recent Developments and Future Plans
2.22 Gilead Sciences
2.22.1 Gilead Sciences Details
2.22.2 Gilead Sciences Major Business
2.22.3 Gilead Sciences Oncology Drugs Product and Solutions
2.22.4 Gilead Sciences Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.22.5 Gilead Sciences Recent Developments and Future Plans
2.23 Hengrui Medicine
2.23.1 Hengrui Medicine Details
2.23.2 Hengrui Medicine Major Business
2.23.3 Hengrui Medicine Oncology Drugs Product and Solutions
2.23.4 Hengrui Medicine Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.23.5 Hengrui Medicine Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Oncology Drugs Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Oncology Drugs by Company Revenue
3.2.2 Top 3 Oncology Drugs Players Market Share in 2024
3.2.3 Top 6 Oncology Drugs Players Market Share in 2024
3.3 Oncology Drugs Market: Overall Company Footprint Analysis
3.3.1 Oncology Drugs Market: Region Footprint
3.3.2 Oncology Drugs Market: Company Product Type Footprint
3.3.3 Oncology Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Oncology Drugs Consumption Value and Market Share by Type (2020-2025)
4.2 Global Oncology Drugs Market Forecast by Type (2026-2031)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Oncology Drugs Consumption Value Market Share by Application (2020-2025)
5.2 Global Oncology Drugs Market Forecast by Application (2026-2031)
6 NORTH AMERICA
6.1 North America Oncology Drugs Consumption Value by Type (2020-2031)
6.2 North America Oncology Drugs Market Size by Application (2020-2031)
6.3 North America Oncology Drugs Market Size by Country
6.3.1 North America Oncology Drugs Consumption Value by Country (2020-2031)
6.3.2 United States Oncology Drugs Market Size and Forecast (2020-2031)
6.3.3 Canada Oncology Drugs Market Size and Forecast (2020-2031)
6.3.4 Mexico Oncology Drugs Market Size and Forecast (2020-2031)
7 EUROPE
7.1 Europe Oncology Drugs Consumption Value by Type (2020-2031)
7.2 Europe Oncology Drugs Consumption Value by Application (2020-2031)
7.3 Europe Oncology Drugs Market Size by Country
7.3.1 Europe Oncology Drugs Consumption Value by Country (2020-2031)
7.3.2 Germany Oncology Drugs Market Size and Forecast (2020-2031)
7.3.3 France Oncology Drugs Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Oncology Drugs Market Size and Forecast (2020-2031)
7.3.5 Russia Oncology Drugs Market Size and Forecast (2020-2031)
7.3.6 Italy Oncology Drugs Market Size and Forecast (2020-2031)
8 ASIA-PACIFIC
8.1 Asia-Pacific Oncology Drugs Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Oncology Drugs Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Oncology Drugs Market Size by Region
8.3.1 Asia-Pacific Oncology Drugs Consumption Value by Region (2020-2031)
8.3.2 China Oncology Drugs Market Size and Forecast (2020-2031)
8.3.3 Japan Oncology Drugs Market Size and Forecast (2020-2031)
8.3.4 South Korea Oncology Drugs Market Size and Forecast (2020-2031)
8.3.5 India Oncology Drugs Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Oncology Drugs Market Size and Forecast (2020-2031)
8.3.7 Australia Oncology Drugs Market Size and Forecast (2020-2031)
9 SOUTH AMERICA
9.1 South America Oncology Drugs Consumption Value by Type (2020-2031)
9.2 South America Oncology Drugs Consumption Value by Application (2020-2031)
9.3 South America Oncology Drugs Market Size by Country
9.3.1 South America Oncology Drugs Consumption Value by Country (2020-2031)
9.3.2 Brazil Oncology Drugs Market Size and Forecast (2020-2031)
9.3.3 Argentina Oncology Drugs Market Size and Forecast (2020-2031)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Oncology Drugs Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Oncology Drugs Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Oncology Drugs Market Size by Country
10.3.1 Middle East & Africa Oncology Drugs Consumption Value by Country (2020-2031)
10.3.2 Turkey Oncology Drugs Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Oncology Drugs Market Size and Forecast (2020-2031)
10.3.4 UAE Oncology Drugs Market Size and Forecast (2020-2031)
11 MARKET DYNAMICS
11.1 Oncology Drugs Market Drivers
11.2 Oncology Drugs Market Restraints
11.3 Oncology Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Oncology Drugs Industry Chain
12.2 Oncology Drugs Upstream Analysis
12.3 Oncology Drugs Midstream Analysis
12.4 Oncology Drugs Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Oncology Drugs by Type
1.3.1 Overview: Global Oncology Drugs Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Oncology Drugs Consumption Value Market Share by Type in 2024
1.3.3 Chemotherapy
1.3.4 Targeted Therapy
1.3.5 Immunotherapy (Biologic Therapy)
1.3.6 Hormonal Therapy
1.3.7 Others
1.4 Global Oncology Drugs Market by Application
1.4.1 Overview: Global Oncology Drugs Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Blood Cancer
1.4.3 Breast Cancer
1.4.4 Gastrointestinal Cancer
1.4.5 Prostate Cancer
1.4.6 Respiratory or Lung Cancer
1.4.7 Others
1.5 Global Oncology Drugs Market Size & Forecast
1.6 Global Oncology Drugs Market Size and Forecast by Region
1.6.1 Global Oncology Drugs Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Oncology Drugs Market Size by Region, (2020-2031)
1.6.3 North America Oncology Drugs Market Size and Prospect (2020-2031)
1.6.4 Europe Oncology Drugs Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Oncology Drugs Market Size and Prospect (2020-2031)
1.6.6 South America Oncology Drugs Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Oncology Drugs Market Size and Prospect (2020-2031)
2 COMPANY PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Oncology Drugs Product and Solutions
2.1.4 Roche Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Roche Recent Developments and Future Plans
2.2 Celgene
2.2.1 Celgene Details
2.2.2 Celgene Major Business
2.2.3 Celgene Oncology Drugs Product and Solutions
2.2.4 Celgene Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Celgene Recent Developments and Future Plans
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis Oncology Drugs Product and Solutions
2.3.4 Novartis Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Novartis Recent Developments and Future Plans
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb Details
2.4.2 Bristol-Myers Squibb Major Business
2.4.3 Bristol-Myers Squibb Oncology Drugs Product and Solutions
2.4.4 Bristol-Myers Squibb Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business
2.5.3 Johnson & Johnson Oncology Drugs Product and Solutions
2.5.4 Johnson & Johnson Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Johnson & Johnson Recent Developments and Future Plans
2.6 Merck & Co.
2.6.1 Merck & Co. Details
2.6.2 Merck & Co. Major Business
2.6.3 Merck & Co. Oncology Drugs Product and Solutions
2.6.4 Merck & Co. Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Merck & Co. Recent Developments and Future Plans
2.7 AstraZeneca
2.7.1 AstraZeneca Details
2.7.2 AstraZeneca Major Business
2.7.3 AstraZeneca Oncology Drugs Product and Solutions
2.7.4 AstraZeneca Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 AstraZeneca Recent Developments and Future Plans
2.8 Pfizer
2.8.1 Pfizer Details
2.8.2 Pfizer Major Business
2.8.3 Pfizer Oncology Drugs Product and Solutions
2.8.4 Pfizer Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Pfizer Recent Developments and Future Plans
2.9 Amgen
2.9.1 Amgen Details
2.9.2 Amgen Major Business
2.9.3 Amgen Oncology Drugs Product and Solutions
2.9.4 Amgen Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Amgen Recent Developments and Future Plans
2.10 Eli Lilly
2.10.1 Eli Lilly Details
2.10.2 Eli Lilly Major Business
2.10.3 Eli Lilly Oncology Drugs Product and Solutions
2.10.4 Eli Lilly Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Eli Lilly Recent Developments and Future Plans
2.11 AbbVie
2.11.1 AbbVie Details
2.11.2 AbbVie Major Business
2.11.3 AbbVie Oncology Drugs Product and Solutions
2.11.4 AbbVie Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 AbbVie Recent Developments and Future Plans
2.12 Takeda
2.12.1 Takeda Details
2.12.2 Takeda Major Business
2.12.3 Takeda Oncology Drugs Product and Solutions
2.12.4 Takeda Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Takeda Recent Developments and Future Plans
2.13 Astellas
2.13.1 Astellas Details
2.13.2 Astellas Major Business
2.13.3 Astellas Oncology Drugs Product and Solutions
2.13.4 Astellas Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.13.5 Astellas Recent Developments and Future Plans
2.14 Ipsen
2.14.1 Ipsen Details
2.14.2 Ipsen Major Business
2.14.3 Ipsen Oncology Drugs Product and Solutions
2.14.4 Ipsen Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.14.5 Ipsen Recent Developments and Future Plans
2.15 Sanofi
2.15.1 Sanofi Details
2.15.2 Sanofi Major Business
2.15.3 Sanofi Oncology Drugs Product and Solutions
2.15.4 Sanofi Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.15.5 Sanofi Recent Developments and Future Plans
2.16 Bayer
2.16.1 Bayer Details
2.16.2 Bayer Major Business
2.16.3 Bayer Oncology Drugs Product and Solutions
2.16.4 Bayer Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.16.5 Bayer Recent Developments and Future Plans
2.17 Biogen Idec
2.17.1 Biogen Idec Details
2.17.2 Biogen Idec Major Business
2.17.3 Biogen Idec Oncology Drugs Product and Solutions
2.17.4 Biogen Idec Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.17.5 Biogen Idec Recent Developments and Future Plans
2.18 Teva
2.18.1 Teva Details
2.18.2 Teva Major Business
2.18.3 Teva Oncology Drugs Product and Solutions
2.18.4 Teva Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.18.5 Teva Recent Developments and Future Plans
2.19 Otsuka
2.19.1 Otsuka Details
2.19.2 Otsuka Major Business
2.19.3 Otsuka Oncology Drugs Product and Solutions
2.19.4 Otsuka Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.19.5 Otsuka Recent Developments and Future Plans
2.20 Eisai
2.20.1 Eisai Details
2.20.2 Eisai Major Business
2.20.3 Eisai Oncology Drugs Product and Solutions
2.20.4 Eisai Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.20.5 Eisai Recent Developments and Future Plans
2.21 Merck KGaA
2.21.1 Merck KGaA Details
2.21.2 Merck KGaA Major Business
2.21.3 Merck KGaA Oncology Drugs Product and Solutions
2.21.4 Merck KGaA Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.21.5 Merck KGaA Recent Developments and Future Plans
2.22 Gilead Sciences
2.22.1 Gilead Sciences Details
2.22.2 Gilead Sciences Major Business
2.22.3 Gilead Sciences Oncology Drugs Product and Solutions
2.22.4 Gilead Sciences Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.22.5 Gilead Sciences Recent Developments and Future Plans
2.23 Hengrui Medicine
2.23.1 Hengrui Medicine Details
2.23.2 Hengrui Medicine Major Business
2.23.3 Hengrui Medicine Oncology Drugs Product and Solutions
2.23.4 Hengrui Medicine Oncology Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.23.5 Hengrui Medicine Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Oncology Drugs Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Oncology Drugs by Company Revenue
3.2.2 Top 3 Oncology Drugs Players Market Share in 2024
3.2.3 Top 6 Oncology Drugs Players Market Share in 2024
3.3 Oncology Drugs Market: Overall Company Footprint Analysis
3.3.1 Oncology Drugs Market: Region Footprint
3.3.2 Oncology Drugs Market: Company Product Type Footprint
3.3.3 Oncology Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Oncology Drugs Consumption Value and Market Share by Type (2020-2025)
4.2 Global Oncology Drugs Market Forecast by Type (2026-2031)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Oncology Drugs Consumption Value Market Share by Application (2020-2025)
5.2 Global Oncology Drugs Market Forecast by Application (2026-2031)
6 NORTH AMERICA
6.1 North America Oncology Drugs Consumption Value by Type (2020-2031)
6.2 North America Oncology Drugs Market Size by Application (2020-2031)
6.3 North America Oncology Drugs Market Size by Country
6.3.1 North America Oncology Drugs Consumption Value by Country (2020-2031)
6.3.2 United States Oncology Drugs Market Size and Forecast (2020-2031)
6.3.3 Canada Oncology Drugs Market Size and Forecast (2020-2031)
6.3.4 Mexico Oncology Drugs Market Size and Forecast (2020-2031)
7 EUROPE
7.1 Europe Oncology Drugs Consumption Value by Type (2020-2031)
7.2 Europe Oncology Drugs Consumption Value by Application (2020-2031)
7.3 Europe Oncology Drugs Market Size by Country
7.3.1 Europe Oncology Drugs Consumption Value by Country (2020-2031)
7.3.2 Germany Oncology Drugs Market Size and Forecast (2020-2031)
7.3.3 France Oncology Drugs Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Oncology Drugs Market Size and Forecast (2020-2031)
7.3.5 Russia Oncology Drugs Market Size and Forecast (2020-2031)
7.3.6 Italy Oncology Drugs Market Size and Forecast (2020-2031)
8 ASIA-PACIFIC
8.1 Asia-Pacific Oncology Drugs Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Oncology Drugs Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Oncology Drugs Market Size by Region
8.3.1 Asia-Pacific Oncology Drugs Consumption Value by Region (2020-2031)
8.3.2 China Oncology Drugs Market Size and Forecast (2020-2031)
8.3.3 Japan Oncology Drugs Market Size and Forecast (2020-2031)
8.3.4 South Korea Oncology Drugs Market Size and Forecast (2020-2031)
8.3.5 India Oncology Drugs Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Oncology Drugs Market Size and Forecast (2020-2031)
8.3.7 Australia Oncology Drugs Market Size and Forecast (2020-2031)
9 SOUTH AMERICA
9.1 South America Oncology Drugs Consumption Value by Type (2020-2031)
9.2 South America Oncology Drugs Consumption Value by Application (2020-2031)
9.3 South America Oncology Drugs Market Size by Country
9.3.1 South America Oncology Drugs Consumption Value by Country (2020-2031)
9.3.2 Brazil Oncology Drugs Market Size and Forecast (2020-2031)
9.3.3 Argentina Oncology Drugs Market Size and Forecast (2020-2031)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Oncology Drugs Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Oncology Drugs Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Oncology Drugs Market Size by Country
10.3.1 Middle East & Africa Oncology Drugs Consumption Value by Country (2020-2031)
10.3.2 Turkey Oncology Drugs Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Oncology Drugs Market Size and Forecast (2020-2031)
10.3.4 UAE Oncology Drugs Market Size and Forecast (2020-2031)
11 MARKET DYNAMICS
11.1 Oncology Drugs Market Drivers
11.2 Oncology Drugs Market Restraints
11.3 Oncology Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Oncology Drugs Industry Chain
12.2 Oncology Drugs Upstream Analysis
12.3 Oncology Drugs Midstream Analysis
12.4 Oncology Drugs Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Oncology Drugs Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Oncology Drugs Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Global Oncology Drugs Consumption Value by Region (2020-2025) & (USD Million)
Table 4. Global Oncology Drugs Consumption Value by Region (2026-2031) & (USD Million)
Table 5. Roche Company Information, Head Office, and Major Competitors
Table 6. Roche Major Business
Table 7. Roche Oncology Drugs Product and Solutions
Table 8. Roche Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 9. Roche Recent Developments and Future Plans
Table 10. Celgene Company Information, Head Office, and Major Competitors
Table 11. Celgene Major Business
Table 12. Celgene Oncology Drugs Product and Solutions
Table 13. Celgene Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 14. Celgene Recent Developments and Future Plans
Table 15. Novartis Company Information, Head Office, and Major Competitors
Table 16. Novartis Major Business
Table 17. Novartis Oncology Drugs Product and Solutions
Table 18. Novartis Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 19. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
Table 20. Bristol-Myers Squibb Major Business
Table 21. Bristol-Myers Squibb Oncology Drugs Product and Solutions
Table 22. Bristol-Myers Squibb Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 23. Bristol-Myers Squibb Recent Developments and Future Plans
Table 24. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 25. Johnson & Johnson Major Business
Table 26. Johnson & Johnson Oncology Drugs Product and Solutions
Table 27. Johnson & Johnson Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 28. Johnson & Johnson Recent Developments and Future Plans
Table 29. Merck & Co. Company Information, Head Office, and Major Competitors
Table 30. Merck & Co. Major Business
Table 31. Merck & Co. Oncology Drugs Product and Solutions
Table 32. Merck & Co. Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 33. Merck & Co. Recent Developments and Future Plans
Table 34. AstraZeneca Company Information, Head Office, and Major Competitors
Table 35. AstraZeneca Major Business
Table 36. AstraZeneca Oncology Drugs Product and Solutions
Table 37. AstraZeneca Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 38. AstraZeneca Recent Developments and Future Plans
Table 39. Pfizer Company Information, Head Office, and Major Competitors
Table 40. Pfizer Major Business
Table 41. Pfizer Oncology Drugs Product and Solutions
Table 42. Pfizer Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 43. Pfizer Recent Developments and Future Plans
Table 44. Amgen Company Information, Head Office, and Major Competitors
Table 45. Amgen Major Business
Table 46. Amgen Oncology Drugs Product and Solutions
Table 47. Amgen Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 48. Amgen Recent Developments and Future Plans
Table 49. Eli Lilly Company Information, Head Office, and Major Competitors
Table 50. Eli Lilly Major Business
Table 51. Eli Lilly Oncology Drugs Product and Solutions
Table 52. Eli Lilly Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 53. Eli Lilly Recent Developments and Future Plans
Table 54. AbbVie Company Information, Head Office, and Major Competitors
Table 55. AbbVie Major Business
Table 56. AbbVie Oncology Drugs Product and Solutions
Table 57. AbbVie Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 58. AbbVie Recent Developments and Future Plans
Table 59. Takeda Company Information, Head Office, and Major Competitors
Table 60. Takeda Major Business
Table 61. Takeda Oncology Drugs Product and Solutions
Table 62. Takeda Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 63. Takeda Recent Developments and Future Plans
Table 64. Astellas Company Information, Head Office, and Major Competitors
Table 65. Astellas Major Business
Table 66. Astellas Oncology Drugs Product and Solutions
Table 67. Astellas Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 68. Astellas Recent Developments and Future Plans
Table 69. Ipsen Company Information, Head Office, and Major Competitors
Table 70. Ipsen Major Business
Table 71. Ipsen Oncology Drugs Product and Solutions
Table 72. Ipsen Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 73. Ipsen Recent Developments and Future Plans
Table 74. Sanofi Company Information, Head Office, and Major Competitors
Table 75. Sanofi Major Business
Table 76. Sanofi Oncology Drugs Product and Solutions
Table 77. Sanofi Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 78. Sanofi Recent Developments and Future Plans
Table 79. Bayer Company Information, Head Office, and Major Competitors
Table 80. Bayer Major Business
Table 81. Bayer Oncology Drugs Product and Solutions
Table 82. Bayer Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 83. Bayer Recent Developments and Future Plans
Table 84. Biogen Idec Company Information, Head Office, and Major Competitors
Table 85. Biogen Idec Major Business
Table 86. Biogen Idec Oncology Drugs Product and Solutions
Table 87. Biogen Idec Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 88. Biogen Idec Recent Developments and Future Plans
Table 89. Teva Company Information, Head Office, and Major Competitors
Table 90. Teva Major Business
Table 91. Teva Oncology Drugs Product and Solutions
Table 92. Teva Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 93. Teva Recent Developments and Future Plans
Table 94. Otsuka Company Information, Head Office, and Major Competitors
Table 95. Otsuka Major Business
Table 96. Otsuka Oncology Drugs Product and Solutions
Table 97. Otsuka Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 98. Otsuka Recent Developments and Future Plans
Table 99. Eisai Company Information, Head Office, and Major Competitors
Table 100. Eisai Major Business
Table 101. Eisai Oncology Drugs Product and Solutions
Table 102. Eisai Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 103. Eisai Recent Developments and Future Plans
Table 104. Merck KGaA Company Information, Head Office, and Major Competitors
Table 105. Merck KGaA Major Business
Table 106. Merck KGaA Oncology Drugs Product and Solutions
Table 107. Merck KGaA Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 108. Merck KGaA Recent Developments and Future Plans
Table 109. Gilead Sciences Company Information, Head Office, and Major Competitors
Table 110. Gilead Sciences Major Business
Table 111. Gilead Sciences Oncology Drugs Product and Solutions
Table 112. Gilead Sciences Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 113. Gilead Sciences Recent Developments and Future Plans
Table 114. Hengrui Medicine Company Information, Head Office, and Major Competitors
Table 115. Hengrui Medicine Major Business
Table 116. Hengrui Medicine Oncology Drugs Product and Solutions
Table 117. Hengrui Medicine Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 118. Hengrui Medicine Recent Developments and Future Plans
Table 119. Global Oncology Drugs Revenue (USD Million) by Players (2020-2025)
Table 120. Global Oncology Drugs Revenue Share by Players (2020-2025)
Table 121. Breakdown of Oncology Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
Table 122. Market Position of Players in Oncology Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 123. Head Office of Key Oncology Drugs Players
Table 124. Oncology Drugs Market: Company Product Type Footprint
Table 125. Oncology Drugs Market: Company Product Application Footprint
Table 126. Oncology Drugs New Market Entrants and Barriers to Market Entry
Table 127. Oncology Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 128. Global Oncology Drugs Consumption Value (USD Million) by Type (2020-2025)
Table 129. Global Oncology Drugs Consumption Value Share by Type (2020-2025)
Table 130. Global Oncology Drugs Consumption Value Forecast by Type (2026-2031)
Table 131. Global Oncology Drugs Consumption Value by Application (2020-2025)
Table 132. Global Oncology Drugs Consumption Value Forecast by Application (2026-2031)
Table 133. North America Oncology Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 134. North America Oncology Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 135. North America Oncology Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 136. North America Oncology Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 137. North America Oncology Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 138. North America Oncology Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 139. Europe Oncology Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 140. Europe Oncology Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 141. Europe Oncology Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 142. Europe Oncology Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 143. Europe Oncology Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 144. Europe Oncology Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 145. Asia-Pacific Oncology Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 146. Asia-Pacific Oncology Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 147. Asia-Pacific Oncology Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 148. Asia-Pacific Oncology Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 149. Asia-Pacific Oncology Drugs Consumption Value by Region (2020-2025) & (USD Million)
Table 150. Asia-Pacific Oncology Drugs Consumption Value by Region (2026-2031) & (USD Million)
Table 151. South America Oncology Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 152. South America Oncology Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 153. South America Oncology Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 154. South America Oncology Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 155. South America Oncology Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 156. South America Oncology Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 157. Middle East & Africa Oncology Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 158. Middle East & Africa Oncology Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 159. Middle East & Africa Oncology Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 160. Middle East & Africa Oncology Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 161. Middle East & Africa Oncology Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 162. Middle East & Africa Oncology Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 163. Global Key Players of Oncology Drugs Upstream (Raw Materials)
Table 164. Global Oncology Drugs Typical Customers
Table 1. Global Oncology Drugs Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Oncology Drugs Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Global Oncology Drugs Consumption Value by Region (2020-2025) & (USD Million)
Table 4. Global Oncology Drugs Consumption Value by Region (2026-2031) & (USD Million)
Table 5. Roche Company Information, Head Office, and Major Competitors
Table 6. Roche Major Business
Table 7. Roche Oncology Drugs Product and Solutions
Table 8. Roche Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 9. Roche Recent Developments and Future Plans
Table 10. Celgene Company Information, Head Office, and Major Competitors
Table 11. Celgene Major Business
Table 12. Celgene Oncology Drugs Product and Solutions
Table 13. Celgene Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 14. Celgene Recent Developments and Future Plans
Table 15. Novartis Company Information, Head Office, and Major Competitors
Table 16. Novartis Major Business
Table 17. Novartis Oncology Drugs Product and Solutions
Table 18. Novartis Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 19. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
Table 20. Bristol-Myers Squibb Major Business
Table 21. Bristol-Myers Squibb Oncology Drugs Product and Solutions
Table 22. Bristol-Myers Squibb Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 23. Bristol-Myers Squibb Recent Developments and Future Plans
Table 24. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 25. Johnson & Johnson Major Business
Table 26. Johnson & Johnson Oncology Drugs Product and Solutions
Table 27. Johnson & Johnson Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 28. Johnson & Johnson Recent Developments and Future Plans
Table 29. Merck & Co. Company Information, Head Office, and Major Competitors
Table 30. Merck & Co. Major Business
Table 31. Merck & Co. Oncology Drugs Product and Solutions
Table 32. Merck & Co. Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 33. Merck & Co. Recent Developments and Future Plans
Table 34. AstraZeneca Company Information, Head Office, and Major Competitors
Table 35. AstraZeneca Major Business
Table 36. AstraZeneca Oncology Drugs Product and Solutions
Table 37. AstraZeneca Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 38. AstraZeneca Recent Developments and Future Plans
Table 39. Pfizer Company Information, Head Office, and Major Competitors
Table 40. Pfizer Major Business
Table 41. Pfizer Oncology Drugs Product and Solutions
Table 42. Pfizer Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 43. Pfizer Recent Developments and Future Plans
Table 44. Amgen Company Information, Head Office, and Major Competitors
Table 45. Amgen Major Business
Table 46. Amgen Oncology Drugs Product and Solutions
Table 47. Amgen Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 48. Amgen Recent Developments and Future Plans
Table 49. Eli Lilly Company Information, Head Office, and Major Competitors
Table 50. Eli Lilly Major Business
Table 51. Eli Lilly Oncology Drugs Product and Solutions
Table 52. Eli Lilly Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 53. Eli Lilly Recent Developments and Future Plans
Table 54. AbbVie Company Information, Head Office, and Major Competitors
Table 55. AbbVie Major Business
Table 56. AbbVie Oncology Drugs Product and Solutions
Table 57. AbbVie Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 58. AbbVie Recent Developments and Future Plans
Table 59. Takeda Company Information, Head Office, and Major Competitors
Table 60. Takeda Major Business
Table 61. Takeda Oncology Drugs Product and Solutions
Table 62. Takeda Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 63. Takeda Recent Developments and Future Plans
Table 64. Astellas Company Information, Head Office, and Major Competitors
Table 65. Astellas Major Business
Table 66. Astellas Oncology Drugs Product and Solutions
Table 67. Astellas Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 68. Astellas Recent Developments and Future Plans
Table 69. Ipsen Company Information, Head Office, and Major Competitors
Table 70. Ipsen Major Business
Table 71. Ipsen Oncology Drugs Product and Solutions
Table 72. Ipsen Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 73. Ipsen Recent Developments and Future Plans
Table 74. Sanofi Company Information, Head Office, and Major Competitors
Table 75. Sanofi Major Business
Table 76. Sanofi Oncology Drugs Product and Solutions
Table 77. Sanofi Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 78. Sanofi Recent Developments and Future Plans
Table 79. Bayer Company Information, Head Office, and Major Competitors
Table 80. Bayer Major Business
Table 81. Bayer Oncology Drugs Product and Solutions
Table 82. Bayer Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 83. Bayer Recent Developments and Future Plans
Table 84. Biogen Idec Company Information, Head Office, and Major Competitors
Table 85. Biogen Idec Major Business
Table 86. Biogen Idec Oncology Drugs Product and Solutions
Table 87. Biogen Idec Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 88. Biogen Idec Recent Developments and Future Plans
Table 89. Teva Company Information, Head Office, and Major Competitors
Table 90. Teva Major Business
Table 91. Teva Oncology Drugs Product and Solutions
Table 92. Teva Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 93. Teva Recent Developments and Future Plans
Table 94. Otsuka Company Information, Head Office, and Major Competitors
Table 95. Otsuka Major Business
Table 96. Otsuka Oncology Drugs Product and Solutions
Table 97. Otsuka Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 98. Otsuka Recent Developments and Future Plans
Table 99. Eisai Company Information, Head Office, and Major Competitors
Table 100. Eisai Major Business
Table 101. Eisai Oncology Drugs Product and Solutions
Table 102. Eisai Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 103. Eisai Recent Developments and Future Plans
Table 104. Merck KGaA Company Information, Head Office, and Major Competitors
Table 105. Merck KGaA Major Business
Table 106. Merck KGaA Oncology Drugs Product and Solutions
Table 107. Merck KGaA Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 108. Merck KGaA Recent Developments and Future Plans
Table 109. Gilead Sciences Company Information, Head Office, and Major Competitors
Table 110. Gilead Sciences Major Business
Table 111. Gilead Sciences Oncology Drugs Product and Solutions
Table 112. Gilead Sciences Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 113. Gilead Sciences Recent Developments and Future Plans
Table 114. Hengrui Medicine Company Information, Head Office, and Major Competitors
Table 115. Hengrui Medicine Major Business
Table 116. Hengrui Medicine Oncology Drugs Product and Solutions
Table 117. Hengrui Medicine Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 118. Hengrui Medicine Recent Developments and Future Plans
Table 119. Global Oncology Drugs Revenue (USD Million) by Players (2020-2025)
Table 120. Global Oncology Drugs Revenue Share by Players (2020-2025)
Table 121. Breakdown of Oncology Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
Table 122. Market Position of Players in Oncology Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 123. Head Office of Key Oncology Drugs Players
Table 124. Oncology Drugs Market: Company Product Type Footprint
Table 125. Oncology Drugs Market: Company Product Application Footprint
Table 126. Oncology Drugs New Market Entrants and Barriers to Market Entry
Table 127. Oncology Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 128. Global Oncology Drugs Consumption Value (USD Million) by Type (2020-2025)
Table 129. Global Oncology Drugs Consumption Value Share by Type (2020-2025)
Table 130. Global Oncology Drugs Consumption Value Forecast by Type (2026-2031)
Table 131. Global Oncology Drugs Consumption Value by Application (2020-2025)
Table 132. Global Oncology Drugs Consumption Value Forecast by Application (2026-2031)
Table 133. North America Oncology Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 134. North America Oncology Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 135. North America Oncology Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 136. North America Oncology Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 137. North America Oncology Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 138. North America Oncology Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 139. Europe Oncology Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 140. Europe Oncology Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 141. Europe Oncology Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 142. Europe Oncology Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 143. Europe Oncology Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 144. Europe Oncology Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 145. Asia-Pacific Oncology Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 146. Asia-Pacific Oncology Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 147. Asia-Pacific Oncology Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 148. Asia-Pacific Oncology Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 149. Asia-Pacific Oncology Drugs Consumption Value by Region (2020-2025) & (USD Million)
Table 150. Asia-Pacific Oncology Drugs Consumption Value by Region (2026-2031) & (USD Million)
Table 151. South America Oncology Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 152. South America Oncology Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 153. South America Oncology Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 154. South America Oncology Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 155. South America Oncology Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 156. South America Oncology Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 157. Middle East & Africa Oncology Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 158. Middle East & Africa Oncology Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 159. Middle East & Africa Oncology Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 160. Middle East & Africa Oncology Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 161. Middle East & Africa Oncology Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 162. Middle East & Africa Oncology Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 163. Global Key Players of Oncology Drugs Upstream (Raw Materials)
Table 164. Global Oncology Drugs Typical Customers
LIST OF FIGURES
Figure 1. Oncology Drugs Picture
Figure 2. Global Oncology Drugs Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Oncology Drugs Consumption Value Market Share by Type in 2024
Figure 4. Chemotherapy
Figure 5. Targeted Therapy
Figure 6. Immunotherapy (Biologic Therapy)
Figure 7. Hormonal Therapy
Figure 8. Others
Figure 9. Global Oncology Drugs Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 10. Oncology Drugs Consumption Value Market Share by Application in 2024
Figure 11. Blood Cancer Picture
Figure 12. Breast Cancer Picture
Figure 13. Gastrointestinal Cancer Picture
Figure 14. Prostate Cancer Picture
Figure 15. Respiratory or Lung Cancer Picture
Figure 16. Others Picture
Figure 17. Global Oncology Drugs Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 18. Global Oncology Drugs Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 19. Global Market Oncology Drugs Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
Figure 20. Global Oncology Drugs Consumption Value Market Share by Region (2020-2031)
Figure 21. Global Oncology Drugs Consumption Value Market Share by Region in 2024
Figure 22. North America Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 23. Europe Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 24. Asia-Pacific Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 25. South America Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 26. Middle East & Africa Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 27. Company Three Recent Developments and Future Plans
Figure 28. Global Oncology Drugs Revenue Share by Players in 2024
Figure 29. Oncology Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 30. Market Share of Oncology Drugs by Player Revenue in 2024
Figure 31. Top 3 Oncology Drugs Players Market Share in 2024
Figure 32. Top 6 Oncology Drugs Players Market Share in 2024
Figure 33. Global Oncology Drugs Consumption Value Share by Type (2020-2025)
Figure 34. Global Oncology Drugs Market Share Forecast by Type (2026-2031)
Figure 35. Global Oncology Drugs Consumption Value Share by Application (2020-2025)
Figure 36. Global Oncology Drugs Market Share Forecast by Application (2026-2031)
Figure 37. North America Oncology Drugs Consumption Value Market Share by Type (2020-2031)
Figure 38. North America Oncology Drugs Consumption Value Market Share by Application (2020-2031)
Figure 39. North America Oncology Drugs Consumption Value Market Share by Country (2020-2031)
Figure 40. United States Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 41. Canada Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 42. Mexico Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 43. Europe Oncology Drugs Consumption Value Market Share by Type (2020-2031)
Figure 44. Europe Oncology Drugs Consumption Value Market Share by Application (2020-2031)
Figure 45. Europe Oncology Drugs Consumption Value Market Share by Country (2020-2031)
Figure 46. Germany Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 47. France Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 48. United Kingdom Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 49. Russia Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 50. Italy Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 51. Asia-Pacific Oncology Drugs Consumption Value Market Share by Type (2020-2031)
Figure 52. Asia-Pacific Oncology Drugs Consumption Value Market Share by Application (2020-2031)
Figure 53. Asia-Pacific Oncology Drugs Consumption Value Market Share by Region (2020-2031)
Figure 54. China Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 55. Japan Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 56. South Korea Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 57. India Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 58. Southeast Asia Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 59. Australia Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 60. South America Oncology Drugs Consumption Value Market Share by Type (2020-2031)
Figure 61. South America Oncology Drugs Consumption Value Market Share by Application (2020-2031)
Figure 62. South America Oncology Drugs Consumption Value Market Share by Country (2020-2031)
Figure 63. Brazil Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 64. Argentina Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 65. Middle East & Africa Oncology Drugs Consumption Value Market Share by Type (2020-2031)
Figure 66. Middle East & Africa Oncology Drugs Consumption Value Market Share by Application (2020-2031)
Figure 67. Middle East & Africa Oncology Drugs Consumption Value Market Share by Country (2020-2031)
Figure 68. Turkey Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 69. Saudi Arabia Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 70. UAE Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 71. Oncology Drugs Market Drivers
Figure 72. Oncology Drugs Market Restraints
Figure 73. Oncology Drugs Market Trends
Figure 74. Porters Five Forces Analysis
Figure 75. Oncology Drugs Industrial Chain
Figure 76. Methodology
Figure 77. Research Process and Data Source
Figure 1. Oncology Drugs Picture
Figure 2. Global Oncology Drugs Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Oncology Drugs Consumption Value Market Share by Type in 2024
Figure 4. Chemotherapy
Figure 5. Targeted Therapy
Figure 6. Immunotherapy (Biologic Therapy)
Figure 7. Hormonal Therapy
Figure 8. Others
Figure 9. Global Oncology Drugs Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 10. Oncology Drugs Consumption Value Market Share by Application in 2024
Figure 11. Blood Cancer Picture
Figure 12. Breast Cancer Picture
Figure 13. Gastrointestinal Cancer Picture
Figure 14. Prostate Cancer Picture
Figure 15. Respiratory or Lung Cancer Picture
Figure 16. Others Picture
Figure 17. Global Oncology Drugs Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 18. Global Oncology Drugs Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 19. Global Market Oncology Drugs Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
Figure 20. Global Oncology Drugs Consumption Value Market Share by Region (2020-2031)
Figure 21. Global Oncology Drugs Consumption Value Market Share by Region in 2024
Figure 22. North America Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 23. Europe Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 24. Asia-Pacific Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 25. South America Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 26. Middle East & Africa Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 27. Company Three Recent Developments and Future Plans
Figure 28. Global Oncology Drugs Revenue Share by Players in 2024
Figure 29. Oncology Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 30. Market Share of Oncology Drugs by Player Revenue in 2024
Figure 31. Top 3 Oncology Drugs Players Market Share in 2024
Figure 32. Top 6 Oncology Drugs Players Market Share in 2024
Figure 33. Global Oncology Drugs Consumption Value Share by Type (2020-2025)
Figure 34. Global Oncology Drugs Market Share Forecast by Type (2026-2031)
Figure 35. Global Oncology Drugs Consumption Value Share by Application (2020-2025)
Figure 36. Global Oncology Drugs Market Share Forecast by Application (2026-2031)
Figure 37. North America Oncology Drugs Consumption Value Market Share by Type (2020-2031)
Figure 38. North America Oncology Drugs Consumption Value Market Share by Application (2020-2031)
Figure 39. North America Oncology Drugs Consumption Value Market Share by Country (2020-2031)
Figure 40. United States Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 41. Canada Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 42. Mexico Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 43. Europe Oncology Drugs Consumption Value Market Share by Type (2020-2031)
Figure 44. Europe Oncology Drugs Consumption Value Market Share by Application (2020-2031)
Figure 45. Europe Oncology Drugs Consumption Value Market Share by Country (2020-2031)
Figure 46. Germany Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 47. France Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 48. United Kingdom Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 49. Russia Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 50. Italy Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 51. Asia-Pacific Oncology Drugs Consumption Value Market Share by Type (2020-2031)
Figure 52. Asia-Pacific Oncology Drugs Consumption Value Market Share by Application (2020-2031)
Figure 53. Asia-Pacific Oncology Drugs Consumption Value Market Share by Region (2020-2031)
Figure 54. China Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 55. Japan Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 56. South Korea Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 57. India Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 58. Southeast Asia Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 59. Australia Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 60. South America Oncology Drugs Consumption Value Market Share by Type (2020-2031)
Figure 61. South America Oncology Drugs Consumption Value Market Share by Application (2020-2031)
Figure 62. South America Oncology Drugs Consumption Value Market Share by Country (2020-2031)
Figure 63. Brazil Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 64. Argentina Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 65. Middle East & Africa Oncology Drugs Consumption Value Market Share by Type (2020-2031)
Figure 66. Middle East & Africa Oncology Drugs Consumption Value Market Share by Application (2020-2031)
Figure 67. Middle East & Africa Oncology Drugs Consumption Value Market Share by Country (2020-2031)
Figure 68. Turkey Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 69. Saudi Arabia Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 70. UAE Oncology Drugs Consumption Value (2020-2031) & (USD Million)
Figure 71. Oncology Drugs Market Drivers
Figure 72. Oncology Drugs Market Restraints
Figure 73. Oncology Drugs Market Trends
Figure 74. Porters Five Forces Analysis
Figure 75. Oncology Drugs Industrial Chain
Figure 76. Methodology
Figure 77. Research Process and Data Source
